Report Overview

The global breast cancer therapeutic market size stood at around USD 21.58 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Breast cancer refers to malignant and invasive tumours in the breast, which can have varying types of presentations. The incidence of breast cancer has increased worldwide in the recent decades.

Breast cancer was ranked eighth in the top 10 causes of death in Netherlands in 2019. It is the most common cancer in women with 26% of the total cancer diagnosis. Statistics show that 1 in 7 women develop breast cancer in Netherlands as opposed to 1 in 150 males. Netherlands has a breast cancer related Disability Adjusted Life-Year (DALYs) burden of approximately of 1100 DALYs per 100,000 women.

In 2017, health care expenditures for breast cancer totalled 870 million euros in Netherlands. This corresponds to 14.8% of the total health care expenditure for new developments and 1.0% of the total health care costs in the Netherlands. In 2017, 81.4% of breast cancer care expenditure went to hospital care. Public health care (including preventive care) was responsible for 8.5%. This expenditure was mainly spent on breast cancer screening.



Market Drivers

The prevalence of breast cancer in Netherlands is amongst the highest in the world. According to Netherlands Cancer Registry (IKNL), the 5-year prevalence of female breast cancer in 2020 and male breast cancer was 77,333 and 529 respectively. This increase in prevalence can be contributed to a variety of factors like short breast feeding period, increasing alcohol consumption, smoking and use of hormone replacement therapy.

The market will also be driven due to recurrence of breast cancer. The recurrence rates can range from 3.7% to 7.1% depending upon the type of breast cancer.

Development of new technologies and increasing awareness is also expected to drive the breast cancer market.